Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Single-chain type IV collagen (SCCOL-IV), also known as the non-triple helical form of the type IV collagen alpha-1 chain (NTH alpha-1(IV)), is a specialized extracellular matrix protein derived from the COL4A1 gene (Tokunaka et al., 2011). While physiological type IV collagen typically forms a heterotrimeric triple helix essential for basement membrane structure, SCCOL-IV is secreted as a monomeric polypeptide and is predominantly found in the interstitium of malignant tumors (Imamura et al., 2011). It is significantly upregulated during active neovascularization and tumor tissue expansion, where it is thought to facilitate the formation of vascular-like networks (Tokunaka et al., 2011). Because SCCOL-IV is largely absent from normal adult tissues, it serves as a highly specific biomarker for tumor progression and a potential diagnostic tool. Therapeutic interventions targeting SCCOL-IV, such as the monoclonal antibody NK46141, aim to inhibit tumor growth by disrupting pathological vasculogenesis and angiogenesis (Nippon Kayaku, 2015). This specificity for the tumor microenvironment makes SCCOL-IV an attractive target for developing selective anti-cancer therapies with minimal impact on healthy basement membranes.
Inhibition of tumor vasculogenesis and suppression of tumor tissue expansion through targeted binding by monoclonal antibodies that recognize the non-triple helical conformation of the collagen alpha-1(IV) chain.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Single-chain type IV collagen (SCCOL-IV).